Skip to main content
Erschienen in: Wiener klinische Wochenschrift 21-22/2018

15.10.2018 | original article

Abiraterone acetate, enzalutamide and their sequence for castration-resistant prostate cancer

Adherence, survival and hospitalization analysis of a medical claims database

verfasst von: Badereddin Mohamad Al-Ali, Klaus Eredics, Stephan Madersbacher, Ingrid Schauer, MD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 21-22/2018

Einloggen, um Zugang zu erhalten

Summary

Objective

To analyze drug adherence, overall survival (OS) and hospitalization rates of patients with castration-resistant prostate cancer (CRPC) treated with arbiraterone acetate (AA), enzalutamide (ENZ) and their sequence in a real-life setting.

Methods

The database of the largest public insurance company in Austria was analyzed. All CRPC patients with at least one prescription of AA and/or ENZ between September 2013 and August 2016 in the pre-chemotherapy and post-chemotherapy setting were extracted and matched to the Austrian death and hospital admission statistics. Drug adherence was estimated by the medication possession ratio (MPR).

Results

Data of 457 patients (mean age: 74.4 ± 8.5 years) were analyzed. The mean MPR was 90% for AA, 85% for ENZ and 88% for the sequence therapy cohort. The median overall survival (OS) of the entire cohort was 21 months: 15 months for AA, 24 months for ENZ, 26 months for the sequence group, and 10 months for the sequence group after switching. In the post-chemotherapy setting, the median OS was 14 months in AA treatment (mean: 15.8 ± 0.9 months), 19 months in the ENZ treatment (mean: 17.2 ± 1.4 months) and 25 months in the sequence group (mean: 22.7 ± 0.8 months). Median OS in the pre-chemotherapy setting was 25 months (mean: 21.5 ± 1.1 months), 18 months in AA treatment group (mean: 18.9 ± 1.5 months) and 17 months in ENZ treatment group (mean: 18.2 ± 1.9 months). Only 43 (9.4%) patients were not hospitalized during the course of the study. On average patients spent 13% of their remaining life span in hospital care (median 8%, range: 1–34%).

Conclusion

This Austrian prescription database allows some insights into the outcome of CRPC patients treated with AA and ENZ and their sequence in a real-life setting. Drug adherence was satisfactory, OS was shorter for AA and ENZ as compared to the pivotal phase III trials.
Literatur
1.
Zurück zum Zitat Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(2):467–79.CrossRef Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(2):467–79.CrossRef
2.
Zurück zum Zitat Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97.CrossRef Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97.CrossRef
3.
Zurück zum Zitat Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138–48.CrossRef Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138–48.CrossRef
4.
Zurück zum Zitat Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983–92.CrossRef Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983–92.CrossRef
5.
Zurück zum Zitat Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–33.CrossRef Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–33.CrossRef
6.
Zurück zum Zitat Poon DM, Chan K, Lee SH, et al. Abiraterone acetate in metastatic castration-resistant prostate cancer—the unanticipated real-world clinical experience. Bmc Urol. 2016;16:12.CrossRef Poon DM, Chan K, Lee SH, et al. Abiraterone acetate in metastatic castration-resistant prostate cancer—the unanticipated real-world clinical experience. Bmc Urol. 2016;16:12.CrossRef
7.
Zurück zum Zitat Mohamad Al-Ali B, Kramer G, Madersbacher S, Berger I. Abiraterone for castration-resistant prostate cancer: adherence, survival and hospitalization: analysis of a medical claims database. Wien Klin Wochenschr. 2017;129(11–12):380–4.CrossRef Mohamad Al-Ali B, Kramer G, Madersbacher S, Berger I. Abiraterone for castration-resistant prostate cancer: adherence, survival and hospitalization: analysis of a medical claims database. Wien Klin Wochenschr. 2017;129(11–12):380–4.CrossRef
8.
Zurück zum Zitat Sabaté E. Adherence to Long-Term Therapies: Evidence for Action. Geneva: World Health Organization; 2003. p. 673–7. Sabaté E. Adherence to Long-Term Therapies: Evidence for Action. Geneva: World Health Organization; 2003. p. 673–7.
9.
Zurück zum Zitat Smith AD, Olson C, Lyons B, Tran D, Blackburn DF. Adherence to abiraterone among the first 86 recipients after release in Saskatchewan. Curr Oncol. 2015;22(1):64–7.CrossRef Smith AD, Olson C, Lyons B, Tran D, Blackburn DF. Adherence to abiraterone among the first 86 recipients after release in Saskatchewan. Curr Oncol. 2015;22(1):64–7.CrossRef
10.
Zurück zum Zitat Lafeuille MH, Grittner AM, Lefebvre P, et al. Adherence patterns for abiraterone acetate and concomitant prednisone use in patients with prostate cancer. J Manag Care Spec Pharm. 2014;20(5):477–84.PubMed Lafeuille MH, Grittner AM, Lefebvre P, et al. Adherence patterns for abiraterone acetate and concomitant prednisone use in patients with prostate cancer. J Manag Care Spec Pharm. 2014;20(5):477–84.PubMed
11.
Zurück zum Zitat Smith MR, Rathkopf DE, Mulders PF, et al. Efficacy and safety of Abiraterone acetate in elderly (75 years or older) chemotherapy naive patients with metastatic castration resistant prostate cancer. J Urol. 2015;194(5):1277–84.CrossRef Smith MR, Rathkopf DE, Mulders PF, et al. Efficacy and safety of Abiraterone acetate in elderly (75 years or older) chemotherapy naive patients with metastatic castration resistant prostate cancer. J Urol. 2015;194(5):1277–84.CrossRef
12.
Zurück zum Zitat Partridge AH, LaFountain A, Mayer E, et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26(4):556–62.CrossRef Partridge AH, LaFountain A, Mayer E, et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26(4):556–62.CrossRef
13.
Zurück zum Zitat Owusu C, Buist DS, Field TS, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2008;26(4):549–55.CrossRef Owusu C, Buist DS, Field TS, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2008;26(4):549–55.CrossRef
14.
Zurück zum Zitat Grundmark B, Garmo H, Zethelius B, et al. Anti-androgen prescribing patterns, patient treatment adherence and influencing factors; results from the nationwide PCBaSe Sweden. Eur J Clin Pharmacol. 2012;68(12):1619–30.CrossRef Grundmark B, Garmo H, Zethelius B, et al. Anti-androgen prescribing patterns, patient treatment adherence and influencing factors; results from the nationwide PCBaSe Sweden. Eur J Clin Pharmacol. 2012;68(12):1619–30.CrossRef
15.
Zurück zum Zitat Balkrishnan R. Predictors of medication adherence in the elderly. Clin Ther. 1998;20(4):764–71.CrossRef Balkrishnan R. Predictors of medication adherence in the elderly. Clin Ther. 1998;20(4):764–71.CrossRef
16.
Zurück zum Zitat Matsubara N, Uemura H, Satoh T, et al. A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study). Jpn J Clin Oncol. 2014;44(12):1216–26.CrossRef Matsubara N, Uemura H, Satoh T, et al. A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study). Jpn J Clin Oncol. 2014;44(12):1216–26.CrossRef
17.
Zurück zum Zitat Leibowitz-Amit R, Templeton AJ, Omlin A, et al. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2014;25(3):657–62.CrossRef Leibowitz-Amit R, Templeton AJ, Omlin A, et al. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2014;25(3):657–62.CrossRef
18.
Zurück zum Zitat Kluetz PG, Ning YM, Maher VE, et al. Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res. 2013;19(24):6650–6.CrossRef Kluetz PG, Ning YM, Maher VE, et al. Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res. 2013;19(24):6650–6.CrossRef
19.
Zurück zum Zitat Gupta E, Guthrie T, Tan W. Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC). Bmc Urol. 2014;14:55.CrossRef Gupta E, Guthrie T, Tan W. Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC). Bmc Urol. 2014;14:55.CrossRef
20.
Zurück zum Zitat Goodman OB Jr., Flaig TW, Molina A, et al. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2014;17(1):34–9.CrossRef Goodman OB Jr., Flaig TW, Molina A, et al. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2014;17(1):34–9.CrossRef
21.
Zurück zum Zitat de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005.CrossRef de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005.CrossRef
Metadaten
Titel
Abiraterone acetate, enzalutamide and their sequence for castration-resistant prostate cancer
Adherence, survival and hospitalization analysis of a medical claims database
verfasst von
Badereddin Mohamad Al-Ali
Klaus Eredics
Stephan Madersbacher
Ingrid Schauer, MD
Publikationsdatum
15.10.2018
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 21-22/2018
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-018-1394-0

Weitere Artikel der Ausgabe 21-22/2018

Wiener klinische Wochenschrift 21-22/2018 Zur Ausgabe